March 2026 FDA Recall Drug by Payless Compounders, Llc
D-0471-2026 - Lack of Assurance of Sterility

This Class II drug recall was voluntarily initiated by Payless Compounders, Llc on March 6, 2026 for the product Drug. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed in OR and the recall is currently ongoing.

Recall Number: D-0471-2026

Reason for Recall
Lack of Assurance of Sterility
Initiated
03-06-2026
Reported
04-22-2026
Quantity
91 vials

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
98646
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Ongoing
Recalling Firm About Recalling Firm
The firm responsible for the recall.
PAYLESS COMPOUNDERS, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
OR
Product Description About Product Description
Full technical description of the product.
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR

Batch or Lot Expiration Information

Lot# Lot Number [email protected]